Amendments to the Claims

Please cancel Claims 8, 9, 11-18, 20, 21, 23-30, 32, 33, 35-42, 44-46, 53, 54, 56-63, 65, 66, 68-75, 77, 78, 80-87, 89-91, 93, and 97-139. Please amend Claims 10, 22, 34, 55, 67, 79 and 92. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Original) A compound represented by the following Structural Formula:



and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of



and ;

(b) R1 is selected from the group consisting of hydrogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, wherein C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents independently selected from R1';

(c) R1′, R26, R27, R28, R31, Z14′, and Z15′ are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, optionally substituted aryloxy, optionally substituted aryl-C_{0-4}-alkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, $OS(O)_2R16$, $N(R17)_2$, NR18C(O)R19, $NR20SO_2R21$, SR22, S(O)R23, $S(O)_2R24$, and $S(O)_2N(R25)_2$; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(d) R2 is selected from the group consisting of C_0-C_8 alkyl and C_{1-6}-heteroalkyl;

(e) X is selected from the group consisting of a bond, O, S, $S(O)_2$ and N;

(f) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30;

(g) Y is selected from the group consisting of C, O, S, NH and a single bond;

(h) E is C(R3)(R4)A or A and wherein

(i) A is selected from the group consisting of C_0-C_6 alkylcarboxyl, C_0-C_6 alkyltetrazole, C_1-C_6 alkylnitrile, C_0-C_6 alkylcarboxamide, C_0-C_6 alkylsulfonamide and C_0-C_6 alkylacylsulfonamide; wherein C_0-C_6 alkylsulfonamide, C_0-C_6 alkylacylsulfonamide and C_0-C_6 alkyltetrazole are each optionally substituted with from one to two groups independently selected from R^7;

(ii) each R^7 is independently selected from the group consisting of hydrogen, C_1-C_6 haloalkyl, aryl-C_0-C_4 alkyl and C_1-C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7′; each R7′ is independently selected from halo, C_1-C_6 alkyl, and haloC_1-C_6 alkyl;

(iii) R3 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, and

C_1-C_5 alkoxy; and

(iv) R4 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_1-C_5 alkoxy, aryloxy, C_3-C_6 cycloalkyl, and aryl C_0-C_4 alkyl, and R3 and R4 are optionally combined to form a C_3-C_4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;

(i) Z5 is S or O;

(j) Z12 is selected from the group consisting of hydrogen and -Z13C_0–C_3alkylZ14;

(k) Z13 is selected from the group consisting of a single bond, CO, CO_2, CONZ15, and SO_2;

(l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14′;

(m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15′;

(n) R9 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkylenyl, halo, aryl-C_0-C_4 alkyl, heteroaryl, C_1-C_6 allyl, and OR29, and wherein aryl-C_0-C_4 alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

(o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_0-C_6 alkyl-COOR12″, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, C3-C6 cycloalkylaryl-C_{0-2}-alkyl, aryloxy, C(O)R13′, COOR14′, OC(O)R15′, $OS(O)_2$R16′, $N(R17')_2$, NR18′C(O)R19′, NR20′SO_2R21′, SR22′, S(O)R23′, $S(O)_2$R24′, and $S(O)_2N(R25')_2$; and wherein aryl-C_{0-4}-alkyl, aryl- C_{1-6}-

heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three independently selected from R28;

(p) R12′, R12″, R13′, R14′, R15′, R16′, R17′, R18′, R19′, R20′, R21′, R22′, R23′, R24′, and R25′ are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(q) R30 is selected from the group consisting of C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, and wherein C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;

(r) R32 is selected from the group consisting of a bond, hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 haloalkyl, and C_1-C_6 alkyloxo;

(s) R33 is selected from the group consisting of C2-C8 alkyl, C1-C8 alkoxy, phenyl, thiophene, pyridine, piperidine,  ,  , and  , wherein the C2-C8 alkyl, C1-C8 alkoxy, phenyl, thiophene, pyridine, piperidine,  ,  , and  , are each optionally substituted with R10 and R11; and

(t) provided that when Y is C or a bond, at least one of R1, R2, R3, and R4 is C1-C4 alkyl.

2. (Original) The compound of Claim 1, wherein A is selected from the group consisting of C_0-C_6 alkylcarboxyl, C_0-C_6 alkyltetrazole, C_1-C_6 alkylnitrile, C_0-C_6 alkylsulfonamide and C_0-C_6 alkylacylsulfonamide; wherein C_0-C_6 alkylsulfonamide, C_0-C_6 alkylacylsulfonamide and C_0-C_6 alkyltetrazole are each optionally substituted with from one to two groups independently selected from R^7.

3. (Original) The compound of Claim 1, wherein the compound is represented by the following Structural Formula:



and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of



and

;

(b) R1 is selected from the group consisting of hydrogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, wherein C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-

C_{0-2}-alkyl are each optionally substituted with from one to three substituents independently selected from R1';

(c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryloxy, aryl-C_{0-4}-alkyl, heteroaryl, heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, $OS(O)_2R16$, $N(R17)_2$, NR18C(O)R19, $NR20SO_2R21$, SR22, S(O)R23, $S(O)_2R24$, and $S(O)_2N(R25)_2$; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(d) R2 is selected from the group consisting of C_0-C_8 alkyl and C_{1-6}-heteroalkyl;

(e) X is selected from the group consisting of a bond, O, S, $S(O)_2$ and N;

(f) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30;

(g) Y is selected from the group consisting of C, O, S, NH and a single bond;

(h) E is C(R3)(R4)A or A and wherein

(i) A is selected from the group consisting of carboxyl, tetrazole, C_1-C_6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; wherein sulfonamide, acylsulfonamide and tetrazole are each optionally substituted with from one to two groups independently selected from R^7;

(ii) each R^7 is independently selected from the group consisting of hydrogen, C_1-C_6 haloalkyl, aryl-C_0-C_4 alkyl and C_1-C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C_1-C_6 alkyl, and haloC_1-C_6 alkyl;

(iii) R3 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, and C_1-C_5 alkoxy; and

(iv) R4 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_1-C_5 alkoxy, aryloxy, C_3-C_6 cycloalkyl, and aryl C_0-C_4 alkyl, and R3 and R4 are optionally combined to form a C_3-C_4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;

(i) Z5 is S or O;

(j) Z12 is selected from the group consisting of hydrogen and -Z13C_0–C_3alkylZ14;

(k) Z13 is selected from the group consisting of a single bond, CO, CO_2, CONZ15, and SO_2;

(l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14′;

(m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15′;

(n) R9 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkylenyl, halo, aryl-C_0-C_4 alkyl, heteroaryl, C_1-C_6 allyl, and OR29, and wherein aryl-C_0-C_4 alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

(o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_0-C_6 alkyl-COOR12″, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, C3-C6 cycloalkylaryl-C_{0-2}-alkyl, aryloxy, C(O)R13′, COOR14′, OC(O)R15′, $OS(O)_2R16'$, $N(R17')_2$, NR18′C(O)R19′, NR20′SO_2R21′, SR22′, S(O)R23′, $S(O)_2R24'$, and $S(O)_2N(R25')_2$; and wherein aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are

each optionally substituted with from one to three independently selected from R28;

(p) R12′, R12″, R13′, R14′, R15′, R16′, R17′, R18′, R19′, R20′, R21′, R22′, R23′, R24′, and R25′ are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(q) R30 is selected from the group consisting of C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, and wherein C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;

(r) R32 is selected from the group consisting of a bond, hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 haloalkyl, and C_1-C_6 alkyloxo;

(s) R33 is selected from the group consisting of phenyl, thiophene, pyridine, piperidine,  ,  , and  , wherein the phenyl, thiophene, pyridine, piperidine,  ,  , and  , are each optionally substituted with R10 and R11; and

(u) provided that when Y is C or a bond, R1, R2, R3, and R4 are each independently C1-C4 alkyl.

4. (Original) The compound of Claim 2, wherein the compound is represented by the following Structural Formula:



5. (Original) The compound of Claim 1, wherein the compound is represented by the following Structural Formula:



6. (Original) The compound of Claim 5, wherein the compound is represented by the following Structural Formula:



7. (Original) The compound of Claim 6, wherein the compound is represented by the following Structural Formula:



8. - 9. (Cancelled)

10. (Currently Amended) The compound of Claim 7, wherein:

X is -O-;

E is -COOH, C_1-C_6 alkylcarboxyl, or C(R3)(R4)-C_1-C_6 alkyl-COOH;

R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12", C_1-C_6 alkoxy, C_1-C_6 haloalkyl, and C_1-C_6 haloalkyloxy;

R9 is selected from the group consisting of hydrogen and C_1-C_3 alkyl;

R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C_1-C_2 alkyl;

R2 is a bond; and

U is saturated C_1-C_3 alkyl optionally substituted with C_1-C_3 alkyl.

11.-18. (Cancelled)

19. (Original) The compound of Claim 6, wherein the compound is represented by the following Structural Formula:



20. - 21. (Cancelled)

22. (Currently Amended) The compound of Claim 19, wherein:

X is -O-;

E is -COOH, C_1-C_6 alkylcarboxyl, or C(R3)(R4)-C_1-C_6 alkyl-COOH;

R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12", C_1-C_6 alkoxy, C_1-C_6 haloalkyl, and C_1-C_6 haloalkyloxy;

R9 is selected from the group consisting of hydrogen and C_1-C_3 alkyl;

R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C_1-C_2 alkyl;

R2 is a bond; and

U is saturated C_1-C_3 alkyl optionally substituted with C_1-C_3 alkyl.

23. - 30. (Cancelled)

31. (Original) The compound of Claim 6, wherein the compound is represented by the following Structural Formula:



32. - 33. (Cancelled)

34. (Currently Amended) The compound of Claim 31, wherein:

X is -O-;

E is -COOH, C_1-C_6 alkylcarboxyl, or C(R3)(R4)-C_1-C_6 alkyl-COOH;

R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12", C_1-C_6 alkoxy, C_1-C_6 haloalkyl, and C_1-C_6 haloalkyloxy;

R9 is selected from the group consisting of hydrogen and C_1-C_3 alkyl;

R1, R3, and R4 are each independently selected from the group consisting of

hydrogen and C_1-C_2 alkyl;

R2 is a bond; and

U is saturated C_1-C_3 alkyl optionally substituted with C_1-C_3 alkyl.

35. - 42. (Cancelled)

43. (Original) The compound of Claim 1 wherein the compound is selected from the group consisting of:

Racemic-(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;

Racemic-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

Racemic-(1-Methyl-6-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(*S*)-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(*R*)-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

Racemic-(6-Hydroxy-5-{1-[4-isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethyl}-1H-indol-3-yl)-acetic acid;

(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid;

(1-Methyl-6-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(6-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid;

(*R*)-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid;

(*S*)-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid;

Racemic-(1-Methyl-6-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

Racemic-(1-Ethyl-6-{2-[4-isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

Racemic-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-propyl-1H-indol-3-yl)-acetic acid;

{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-1H-indol-5-yloxy}-acetic acid;

Racemic(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;

Racemic(6-{1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;

(*R*)-(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;

(*S*)-(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;

(R)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(S)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;

(R)-(1-Methyl-5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(S)-(1-Methyl-5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(1-Methyl-5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;

5-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-propoxy}-1H-indole-2-carboxylic acid; and

5-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-propoxy}-1-methyl-1H-indole-2-carboxylic acid.

44. - 46. (Cancelled)

47. (Original) A compound represented by the following Structural Formula:



and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of



and ;

(b) R1 is selected from the group consisting of hydrogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, wherein C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents independently selected from R1';

(c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6

haloalkyloxy, C_3-C_7 cycloalkyl, optionally substituted aryloxy, optionally substituted aryl-C_{0-4}-alkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, $OS(O)_2R16$, $N(R17)_2$, NR18C(O)R19, $NR20SO_2R21$, SR22, S(O)R23, $S(O)_2R24$, and $S(O)_2N(R25)_2$; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(d) R2 is selected from the group consisting of C_0-C_8 alkyl and C_{1-6}-heteroalkyl;

(e) X is selected from the group consisting of a bond, O, S, $S(O)_2$ and N;

(f) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30;

(g) Y is selected from the group consisting of C, O, S, NH and a single bond;

(h) E is C(R3)(R4)A or A and wherein

(i) A is selected from the group consisting of C_0-C_6 alkylcarboxyl, C_0-C_6 alkyltetrazole, C_1-C_6 alkylnitrile, C_0-C_6 alkylcarboxamide, C_0-C_6 alkylsulfonamide and C_0-C_6 alkylacylsulfonamide; wherein C_0-C_6 alkylsulfonamide, C_0-C_6 alkylacylsulfonamide and C_0-C_6 alkyltetrazole are each optionally substituted with from one to two groups independently selected from R^7;

(ii) each R^7 is independently selected from the group consisting of hydrogen, C_1-C_6 haloalkyl, aryl-C_0-C_4 alkyl and C_1-C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C_1-C_6 alkyl, and haloC_1-C_6 alkyl;

(iii) R3 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, and C_1-C_5 alkoxy; and

(iv) R4 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_1-C_5 alkoxy, aryloxy, C_3-C_6 cycloalkyl, and aryl C_0-C_4 alkyl, and R3 and

R4 are optionally combined to form a C_3-C_4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;

(i) Z5 is S or O;

(j) Z12 is selected from the group consisting of hydrogen and -Z13C_0–C_3alkylZ14;

(k) Z13 is selected from the group consisting of a single bond, CO, CO_2, CONZ15, and SO_2;

(l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14′;

(m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15′;

(n) R9 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkylenyl, halo, aryl-C_0-C_4 alkyl, heteroaryl, C_1-C_6 allyl, and OR29, and wherein aryl-C_0-C_4 alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

(o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_0-C_6 alkyl-COOR12″, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, C3-C6 cycloalkylaryl-C_{0-2}-alkyl, aryloxy, C(O)R13′, COOR14′, OC(O)R15′, $OS(O)_2$R16′, $N(R17')_2$, NR18′C(O)R19′, NR20′SO_2R21′, SR22′, S(O)R23′, $S(O)_2$R24′, and $S(O)_2N(R25')_2$; and wherein aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three independently selected from R28;

(p) R12′, R12″, R13′, R14′, R15′, R16′, R17′, R18′, R19′, R20′, R21′, R22′, R23′, R24′, and R25′ are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(q) R30 is selected from the group consisting of C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, and wherein C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;

(r) R32 is selected from the group consisting of a bond, hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 haloalkyl, and C_1-C_6 alkyloxo;

(s) R33 is selected from the group consisting of C2-C8 alkyl, C1-C8 alkoxy, phenyl, thiophene, pyridine, piperidine,  ,  , and  , wherein the C2-C8 alkyl, C1-C8 alkoxy, phenyl, thiophene, pyridine, piperidine,  ,  , and  , are each optionally substituted with R10 and R11.

48. (Original) The compound of Claim 47, wherein A is selected from the group consisting of C_0-C_6 alkylcarboxyl, C_0-C_6 alkyltetrazole, C_1-C_6 alkylnitrile, C_0-C_6

alkylsulfonamide and C_0-C_6 alkylacylsulfonamide; wherein C_0-C_6 alkylsulfonamide, C_0-C_6 alkylacylsulfonamide and C_0-C_6 alkyltetrazole are each optionally substituted with from one to two groups independently selected from R^7.

49. (Original) The compound of Claim 47, wherein the compound is represented by the following Structural Formula:



and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of



and

;

(b) R1 is selected from the group consisting of hydrogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, wherein C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents independently selected from R1';

(c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6

haloalkyloxy, C_3-C_7 cycloalkyl, aryloxy, aryl-C_{0-4}-alkyl, heteroaryl, heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, $OS(O)_2R16$, $N(R17)_2$, NR18C(O)R19, $NR20SO_2R21$, SR22, S(O)R23, $S(O)_2R24$, and $S(O)_2N(R25)_2$; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(d) R2 is selected from the group consisting of C_0-C_8 alkyl and C_{1-6}-heteroalkyl;

(e) X is selected from the group consisting of a bond, O, S, $S(O)_2$ and N;

(f) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30;

(g) Y is selected from the group consisting of C, O, S, NH and a single bond;

(h) E is C(R3)(R4)A or A and wherein

(i) A is selected from the group consisting of carboxyl, tetrazole, C_1-C_6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; wherein sulfonamide, acylsulfonamide and tetrazole are each optionally substituted with from one to two groups independently selected from R^7;

(ii) each R^7 is independently selected from the group consisting of hydrogen, C_1-C_6 haloalkyl, aryl-C_0-C_4 alkyl and C_1-C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C_1-C_6 alkyl, and haloC_1-C_6 alkyl;

(iii) R3 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, and C_1-C_5 alkoxy; and

(iv) R4 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_1-C_5 alkoxy, aryloxy, C_3-C_6 cycloalkyl, and aryl C_0-C_4 alkyl, and R3 and R4 are optionally combined to form a C_3-C_4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;

(i) Z5 is S or O;

(j) Z12 is selected from the group consisting of hydrogen and -Z13C_0–C_3alkylZ14;

(k) Z13 is selected from the group consisting of a single bond, CO, CO_2, CONZ15, and SO_2;

(l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14′;

(m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15′;

(n) R9 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkylenyl, halo, aryl-C_0-C_4 alkyl, heteroaryl, C_1-C_6 allyl, and OR29, and wherein aryl-C_0-C_4 alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

(o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_0-C_6 alkyl-COOR12″, C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, C3-C6 cycloalkylaryl-C_{0-2}-alkyl, aryloxy, C(O)R13′, COOR14′, OC(O)R15′, $OS(O)_2$R16′, $N(R17')_2$, NR18′C(O)R19′, NR20′SO_2R21′, SR22′, S(O)R23′, $S(O)_2$R24′, and $S(O)_2N(R25')_2$; and wherein aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three independently selected from R28;

(p) R12′, R12″, R13′, R14′, R15′, R16′, R17′, R18′, R19′, R20′, R21′, R22′, R23′, R24′, and R25′ are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(q) R30 is selected from the group consisting of C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl, and wherein C_1-C_6 alkyl, aryl-C_{0-4}-alkyl, aryl- C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6 cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;

(r) R32 is selected from the group consisting of a bond, hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 haloalkyl, and C_1-C_6 alkyloxo;

(s) R33 is selected from the group consisting of phenyl, thiophene, pyridine, piperidine,  ,  , and  , wherein the phenyl, thiophene, pyridine, piperidine,  ,  , and  , are each optionally substituted with R10 and R11.

50. (Original) The compound of Claim 47, wherein the compound is represented by the following Structural Formula:



51. (Original) The compound of Claim 50, wherein the compound is represented by the following Structural Formula:



52. (Original) The compound of Claim 51, wherein the compound is represented by the following Structural Formula:



53. - 54. (Cancelled)

55. (Currently Amended) The compound of Claim 52, wherein:

X is -O-;

E is -COOH, C_1-C_6 alkylcarboxyl, or C(R3)(R4)-C_1-C_6 alkyl-COOH;

R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12", C_1-C_6 alkoxy, C_1-C_6 haloalkyl, and C_1-C_6 haloalkyloxy;

R9 is selected from the group consisting of hydrogen and C_1-C_3 alkyl;

R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C_1-C_2 alkyl;

R2 is a bond; and

U is saturated C_1-C_3 alkyl optionally substituted with C_1-C_3 alkyl.

56. - 63. (Cancelled)

64. (Original) The compound of Claim 51, wherein the compound is represented by the following Structural Formula:



65. - 66. (Cancelled)

67. (Currently Amended) The compound of Claim 64, wherein:

X is -O-;

E is -COOH, C_1-C_6 alkylcarboxyl, or C(R3)(R4)-C_1-C_6 alkyl-COOH;

R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12", C_1-C_6 alkoxy, C_1-C_6 haloalkyl, and C_1-C_6 haloalkyloxy;

R9 is selected from the group consisting of hydrogen and C_1-C_3 alkyl;

R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C_1-C_2 alkyl;

R2 is a bond; and

U is saturated C_1-C_3 alkyl optionally substituted with C_1-C_3 alkyl.

68. - 75. (Cancelled)

76. (Original) The compound of Claim 51, wherein the compound is represented by the following Structural Formula:



77. - 78. (Cancelled)

79. (Currently Amended) The compound of Claim 76, wherein:

X is -O-;

E is -COOH, C_1-C_6 alkylcarboxyl, or C(R3)(R4)-C_1-C_6 alkyl-COOH;

R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C_1-C_6 alkyl, C_1-C_6 alkyl-COOR12", C_1-C_6 alkoxy, C_1-C_6 haloalkyl, and C_1-C_6 haloalkyloxy;

R9 is selected from the group consisting of hydrogen and C_1-C_3 alkyl;

R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C_1-C_2 alkyl;

R2 is a bond; and

U is saturated C_1-C_3 alkyl optionally substituted with C_1-C_3 alkyl.

80. - 87. (Cancelled)

88. (Original) The compound of Claim 47 wherein the compound is selected from the group consisting of:

{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

[5-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-acetic acid;

{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[2-(4-Benzyloxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-(5-{2-[2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;

{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-(5-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;

{5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-{5-[4-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

Racemic 2-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[2-(4-Bromo-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-{5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

Racemic 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

3-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

5-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-pentanoic acid;

5-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-pentanoic acid;

{5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

5-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;

5-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;

5-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-pentanoic acid;

4-[1-(4-Carboxy-butyl)-1H-indol-5-yloxymethyl]-2-(4-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid;

3-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-propionic acid;

3-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

3-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

4-[1-(2-Carboxy-ethyl)-1H-indol-5-yloxymethyl]-2-(4-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid;

{5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-indol-1-yl}-acetic acid;

{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[2-(5-Methyl-2-pyridin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

{5-[2-(5-Methyl-2-morpholin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Methyl-2-(tetrahydro-pyran-4-yl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[2-(2-Butoxy-5-methyl-oxazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

{5-[2-(5-Methyl-2-pyridin-3-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

{5-[2-(5-Methyl-2-pyridin-2-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[3-(4-Butyl-phenoxy)-propoxy]-indol-1-yl}-acetic acid;

(5-{2-[2-(3-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

Racemic 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

3-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

3-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-Methyl-2-(5-{2-[5-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

Racemic-2-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

2-Methyl-2-{5-[4-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

Racemic-2-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

2-Methyl-2-{5-[4-phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-Phenyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-tert-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-propionic acid;

2-{5-[2-(4-Trifluoromethyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-Methyl-2-(5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-(5-{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

2-(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

2-Methyl-2-{5-[2-(5-methyl-2-phenyl-thiazol-4-yl)-ethoxy]-indol-1-yl}-propionic acid;

{5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-2-methyl-indol-1-yl}-acetic acid;

2-{5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

{4-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

Racemic-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-2-phenyl-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

(*R*)-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-ethoxy}-indol-1-yl)-acetic acid;

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-methanesulfonamide;

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-benzenesulfonamide; and

N-[2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetyl]-methanesulfonamide.

89. - 91. (Cancelled)

92. (Currently Amended) A method of treating a mammal in need of treatment for a disease, wherein the disease is treatable by modulating a peroxisome proliferator activated receptor, comprising the step of administering to the mammal in need thereof a therapeutically effective amount of the compound of Claim 1 or 47. ~~a compound represented by the following Structural Formula:~~



~~and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:~~

(a) T1 is selected from the group consisting of



and ;

(b) R1 is selected from the group consisting of hydrogen, C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6-cycloalkylaryl-C_{0-2}-alkyl, wherein C_1-C_8 alkyl, C_1-C_8 alkenyl, aryl-C_{0-4}-alkyl, aryl-C_{1-6}-heteroalkyl, heteroaryl-C_{0-4}-alkyl, and C3-C6-cycloalkylaryl-C_{0-2}-alkyl are each optionally substituted with from one to three substituents independently selected from R1';

(c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_1-C_6-alkyl-COOR12, C_1-C_6-alkoxy, C_1-C_6-haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, optionally substituted aryloxy, optionally substituted aryl-C_{0-4}-alkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, $OS(O)_2R16$, $N(R17)_2$, NR18C(O)R19, $NR20SO_2R21$, SR22, S(O)R23, $S(O)_2R24$, and $S(O)_2N(R25)_2$; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(d) R2 is selected from the group consisting of C_0-C_8 alkyl and C_{1-6}-heteroalkyl;

(e) X is selected from the group consisting of a bond, O, S, $S(O)_2$ and N;

(f) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30;

(g) Y is selected from the group consisting of C, O, S, NH and a single bond;

(h) E is C(R3)(R4)A or A and wherein

(i) A is selected from the group consisting of C_0-C_6 alkylcarboxyl, C_0-C_6 alkyltetrazole, C_1-C_6 alkylnitrile, C_0-C_6 alkylcarboxamide, C_0-C_6 alkylsulfonamide and C_0-C_6 alkylacylsulfonamide; wherein C_0-C_6 alkylsulfonamide, C_0-C_6 alkylacylsulfonamide and C_0-C_6 alkyltetrazole are each optionally substituted with from one to two groups independently selected from R^7;

(ii) each R^7 is independently selected from the group consisting of hydrogen, C_1-C_6 haloalkyl, aryl C_0-C_4 alkyl and C_1-C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7′; each R7′ is independently selected from halo, C_1-C_6 alkyl, and haloC_1-C_6 alkyl;

(iii) R3 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, and C_1-C_5 alkoxy; and

(iv) R4 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, C_1-C_5 alkoxy, aryloxy, C_3-C_6 cycloalkyl, and aryl C_0-C_4 alkyl, and R3 and R4 are optionally combined to form a C_3-C_4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;

(i) Z5 is S or O;

(j) Z12 is selected from the group consisting of hydrogen and -Z13C_0-C_3alkylZ14;

(k) Z13 is selected from the group consisting of a single bond, CO, CO_2, CONZ15, and SO_2;

(l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14′;

(m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15';

(n) R9 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkylenyl, halo, aryl C_0-C_4 alkyl, heteroaryl, C_1-C_6 allyl, and OR29, and wherein aryl C_0-C_4 alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

(o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C_1-C_6 alkyl, C_0-C_6 alkyl-COOR12'', C_1-C_6 alkoxy, C_1-C_6 haloalkyl, C_1-C_6 haloalkyloxy, C_3-C_7 cycloalkyl, aryl C_{0-4} alkyl, aryl C_{1-6} heteroalkyl, heteroaryl C_{0-4} alkyl, C3-C6 cycloalkylaryl C_{0-2} alkyl, aryloxy, C(O)R13', COOR14', OC(O)R15', $OS(O)_2R16'$, $N(R17')_2$, NR18'C(O)R19', NR20'SO_2R21', SR22', S(O)R23', $S(O)_2$R24', and $S(O)_2N(R25')_2$; and wherein aryl C_{0-4} alkyl, aryl C_{1-6} heteroalkyl, heteroaryl C_{0-4} alkyl, and C3-C6 cycloalkylaryl C_{0-2} alkyl are each optionally substituted with from one to three independently selected from R28;

(p) R12', R12'', R13', R14', R15', R16', R17', R18', R19', R20', R21', R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl;

(q) R30 is selected from the group consisting of C_1-C_6 alkyl, aryl C_{0-4} alkyl, aryl C_{1-6} heteroalkyl, heteroaryl C_{0-4} alkyl, and C3-C6 cycloalkylaryl C_{0-2} alkyl, and wherein C_1-C_6 alkyl, aryl C_{0-4} alkyl, aryl C_{1-6} heteroalkyl, heteroaryl C_{0-4} alkyl, and C3-C6 cycloalkylaryl C_{0-2} alkyl are each optionally substituted with from one to three substituents each independently selected from R31;

(r) R32 is selected from the group consisting of a bond, hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 haloalkyl, and C_1-C_6 alkyloxo;

~~(s) R33 is selected from the group consisting of C1-C8 alkyl, C1-C8 alkoxy,~~  ~~phenyl, thiophene, pyridine, piperidine,~~ ~~, and~~  ~~, wherein the C1-C8 alkyl, C1-C8 alkoxy, phenyl, thiophene,~~  ~~pyridine, piperidine,~~ ~~, and~~ ~~, are each optionally substituted with R10 and R11.~~

93. (Cancelled)

94. (Original) The method of Claim 92, wherein the disease is selected from the group consisting of diabetes mellitus, Syndrome X, and atherosclerosis.

95. (Original) The method of Claim 94, wherein the disease is diabetes mellitus.

96. (Original) The method of Claim 94, wherein the disease is Syndrome X.

97. - 139. (Cancelled)

140. (Original) The compound of Claim 1, wherein the compound is selected from the group consisting of:

{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

[5-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-acetic acid;

{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[2-(4-Benzyloxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-(5-{2-[2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;

{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-(5-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;

{5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-{5-[4-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

Racemic 2-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[2-(4-Bromo-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

{5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-{5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

Racemic 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

3-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

5-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-pentanoic acid;

5-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-pentanoic acid;

{5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

5-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;

5-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-pentanoic acid;

3-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-propionic acid;

3-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-indol-1-yl}-acetic acid;

{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[2-(5-Methyl-2-pyridin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

{5-[2-(5-Methyl-2-morpholin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Methyl-2-(tetrahydro-pyran-4-yl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[2-(2-Butoxy-5-methyl-oxazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

{5-[2-(5-Methyl-2-pyridin-3-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

{5-[2-(5-Methyl-2-pyridin-2-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

(5-{2-[2-(3-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

Racemic 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;3-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

3-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-Methyl-2-(5-{2-[5-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

Racemic-2-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

2-Methyl-2-{5-[4-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

Racemic-2-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

2-Methyl-2-{5-[4-phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-tert-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-Methyl-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-propionic acid;

2-{5-[2-(4-Trifluoromethyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

2-Methyl-2-(5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

2-(5-{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

2-(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

2-Methyl-2-{5-[2-(5-methyl-2-phenyl-thiazol-4-yl)-ethoxy]-indol-1-yl}-propionic acid;

{5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-2-methyl-indol-1-yl}-acetic acid;

2-{5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

{4-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

Racemic-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-2-phenyl-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

2-{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;

(*R*)-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

(*S*)-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-ethoxy}-indol-1-yl)-acetic acid;

(*R*)-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-ethoxy}-indol-1-yl)-acetic acid;

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-methanesulfonamide;

N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-benzenesulfonamide; and

N-[2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetyl]-methanesulfonamide.